FAQs

Yes, we believe our pipeline of uses for Prevora and our work in integrating oral health services into chronic disease management support a compelling public offering in the foreseeable future.

Please contact Ross Perry at rossperry@chxtechnologies.com

Expanding the indications for Prevora and forming marketing partnerships in Special Needs Care, Complex Needs Care and Geriatric Care.

The company knows of one drug in Phase II for managing dysbiosis causing dental decay. There is an antibiotic gel, called Arestin, which manages bacteria under gum line. But we know of no other product which can manage dysbiosis above and below the gum line simultaneously and for long periods.   

The structure of Canadian dental insurance favors surgical care over prevention; accordingly, CHX is focused on user-pay and has years of evidence that high risk patients are willing to pay for Prevora regardless of dental insurance coverage.  Health Canada has designated Prevora a medically-necessary drug and, hence, CHX intends to pursue its inclusion in drug benefit plans in Canada.

In other markets such as the UK and US, cost containment pressures are acute. For example, American insurers have published several studies showing that improved oral health reduces hospitalization rates and the use of the Emergency Room, and in turn, reduced health insurance premiums.

Accordingly, we believe Prevora’s ability to improve oral health cost-effectively will be a favorable feature to third-party payers in other markets.

CHX has patents on the composition of the Prevora Stage 2 Sealant, and on the proprietary methods for making and testing Prevora. These are issued in Canada and the EU, with similar applications in the US. CHX is also patenting Prevora’s unique ability to manage both major oral diseases simultaneously, and expects to patent in the use of Prevora in chronic disease management once controlled data become available.